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ABSTRACT
Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive glial tumor 
that occurs in children. The extremely poor median and 5-year survival in children 
afflicted with DIPG highlights the need for novel biology-driven therapeutics. Here, 
we have implicated the chromatin remodeler and regulator of brain development 
called RE1 Silencing Transcription Factor (REST), in DIPG pathology. We show 
that REST protein is aberrantly elevated in at least 21% of DIPG tumors compared 
to normal controls. Its knockdown in DIPG cell lines diminished cell growth and 
decreased their tumorigenicity in mouse intracranial models. DIPGs are vascularized 
tumors and interestingly, REST loss in DIPG cells also caused a substantial decline in 
tumor vasculature as measured by a decrease in CD31 and VEGFR2 staining. These 
observations were validated in vitro, where a significant decline in tube formation by 
human umbilical vein endothelial cells (HUVEC) was seen following REST-loss in DIPG 
cells. Mechanistically, REST controlled the secretion of a pro-angiogenic molecule and 
ligand for VEGFR2 called Gremlin-1 (GREM-1), and was associated with enhanced 
AKT activation. Importantly, the decline in tube formation caused by REST loss could 
be rescued by addition of recombinant GREM-1, which also caused AKT activation in 
HUVECs and human brain microvascular endothelial cells (HBMECs). In summary, 
our study is the first to demonstrate autocrine and paracrine functions for REST in 
DIPG development. It also provides the foundation for future investigations on anti-
angiogenic therapies targeting GREM-1 in combination with drugs that target REST-
associated chromatin remodeling activities.
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INTRODUCTION
Diffuse intrinsic pontine glioma (DIPG) is a highly 
aggressive glial tumor that occurs primarily in children 
between the ages of 5 and 10. DIPG originates in the 
pons, an area of the brain responsible for many essential 
functions such as coordination, breathing and heartbeat 
[1–3]. The median survival period for children with 
DIPG is currently only around 9 months, and the 5-year 
survival is less than 1% [4, 5]. The precarious location 
of the tumor precludes surgery [6–8]. It is also a highly 
infiltrative tumor and chemotherapy has modest efficacy 
at best. Therefore, focal radiation therapy is the current 
accepted standard of care [1, 9, 10]. Thus, there is a clear 
need for new therapies based on a better understanding 
of tumor biology. In the past, lack of DIPG tumor tissue 
and absence of animal models hampered investigations 
on tumor biology and therapeutics discovery. However, 
in recent years, availability of biopsy and access to tumor 
tissue samples resulted in successful development of 
DIPG cell cultures and high throughput genomic analyses 
of DIPG tumors. It has now become possible to pursue 
investigations at the molecular level [11–18].
DIPG are classified as Grade II-IV gliomas that 
include diffuse astrocytoma, anaplastic astrocytoma 
or glioblastoma. Under new WHO classification many 
DIPGs are defined as diffuse midline gliomas with 
H3K27M mutation [19]. The H3K27M mutation is 
a hallmark of more than 80% of DIPGs, implicating 
epigenetic perturbations in DIPG genesis [20]. The role 
of this mutation in tumor development is under active 
investigation in a number of groups [21–26]. Mutations 
in ACVR1 and TP53, amplification in PDGFαR and 
aberrations in MYC and MYCN are also found in a 
sub-set of DIPG patients [14, 27–29]. PI3K and MAPK 
signaling pathways are highly activated in a majority of 
DIPG tumors [30].
Here, we have focused on delineating the role of a 
chromatin remodeler called RE1 Silencing Transcription 
Factor (REST) in DIPG development. REST is a zinc 
finger DNA binding protein and is associated with two 
independent chromatin-remodeling complexes at its 
amino (N-) and carboxy (C-) terminus [31–33]. It is 
regulator of brain development and most studies have 
focused on its function as a negative regulator of neuronal 
lineage specification in embryonic stem cells and neural 
progenitors [34–43]. REST expression is dysregulated in 
various tumors of neural or neural crest origin including 
medulloblastoma [44, 45], glioblastoma [46, 47], Ewings 
sarcoma [48, 49] and neuroblastoma [50–52]. Previous 
work from our group and others has shown that REST 
is important for medulloblastoma progression and 
maintenance [53]. However, REST biology in DIPG has 
not been evaluated thus far.
Here we show that REST gene and protein 
expression is elevated in DIPG samples compared to 
normal controls. It is also expressed to various levels in 
DIPG cell lines. REST loss diminished DIPG cell growth 
in vitro and formation of intracranial tumors. This was 
due to a decrease in cell proliferation. In addition, DIPG 
tumors resulting from cells with REST loss exhibited a 
decrease in CD31, an endothelial marker, and vascular 
endothelial growth factor receptor 2 (VEGFR2) staining. 
In vitro assays revealed a significant decrease in the ability 
of human umbilical vascular endothelial cells (HUVEC) 
to form tubes when cultured in medium harvested from 
DIPG cells where REST expression was knocked down. 
This change in tube formation was not due to endothelial 
cell proliferation. In mechanistic studies, we observed that 
levels of REST and that of the pro-angiogenic protein and 
ligand for VEGFR2, Gremlin-1 (GREM-1), were directly 
correlated in DIPG xenografts. REST knockdown caused 
a decline in secreted GREM-1 as measured by ELISA. 
Knockdown of GREM-1 decreased the ability of DIPG 
cells to support the formation of tubes in vitro by both 
HUVEC and human brain micro-vascular endothelial 
cells (HBMECs). The ability of GREM-1 to promote 
downstream AKT activation in HUVEC and HBMECs 
was confirmed using recombinant GREM-1. Thus, our 
study is the first to implicate REST in DIPG tumors. We 
also demonstrate an autocrine and paracrine function 
for REST in DIPG development. The latter involves 
upregulation of GREM-1 and AKT activation.
RESULTS
REST is expressed at variable levels in human 
DIPG
To evaluate REST expression in DIPG, we obtained 
microarray datasets containing gene expression values 
in human DIPG tumors from Gene Expression Omnibus 
(www.ncbi.nlm.nih.gov/geo) and analyzed through the 
GEO2R interface. REST mRNA levels were significantly 
elevated in DIPG tumor samples (n=35) compared to 
normal brain (n=10). This elevation was particularly 
significant in DIPGs with H3K27M mutation (Figure 
1A). Further, human formalin-fixed paraffin-embedded 
(FFPE) DIPG specimens (n=19) obtained at autopsy were 
subjected to immunohistochemical (IHC) analyses. REST 
expression was scored by a neuropathologist as a negative 
(0)/ weak and focal (+)/ weak, diffuse or multifocal (++)/ 
strong and focal (+++)/or strong, diffuse or multifocal 
(++++). Normal brainstem samples are from patients with 
DIPG tumors, but from a region where tumor was thought 
not to be present. Approximately, 21% of tumors showed 
increased REST expression compared to total number of 
samples analyzed (Figure 1B; Table 1). REST transcript 
and protein levels in three human DIPG (SU) cell lines 
were determined by q-RT-PCR and western blotting. As 
shown in Figure 1C, REST mRNA levels were higher in 
SU-DIPG-IV and SU-DIPG-VI compared to SU-DIPG-
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Figure 1: REST expression is elevated in human DIPG. (A) Gene expression profiles measured by microarray. Gene expression 
datasets deposited in GEO were retrieved and analyzed using GEO2R as described in Materials and Methods. A comparison between 
normal brain samples and a total of 35 DIPG patient samples were shown on the left side. The same set of patient samples were subdivided 
into three distinct subgroups (H3-K27M, silent and MYCN) [16] and were compared with samples of an unknown subgroup on the right 
side. Each dot corresponds to one individual patient. Bars represent mean with standard deviations. *p<0.05; ns=non-significant. (B) 
Hematoxylin-eosin (H&E) and immunohistochemical analysis (IHC) for REST in FFPE DIPG tumor specimens (n=19) and normal pons 
(n=2) was performed as described in materials and methods. Staining was scored by a neuropathologist as negative (0), weak and focal 
(+1), weak diffuse or multifocal (+2), strong and focal (+3), strong diffuse or multifocal (+4). Scale bar, 50μm. REST gene expression and 
protein levels in SU-DIPG-IV, -VI and -XIII cell lines were determined by (C) Q-RT-PCR and (D) Western blotting respectively. GAPDH 
was to normalize REST gene expression. Tubulin served as a loading control for Western blot analysis.
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XIII. However, REST protein levels were higher in SU-
DIPG-IV and SU-DIPG-XIII relative to SU-DIPG-VI 
(Figure 1D).
REST loss blocks DIPG cell growth in vitro and 
in vivo
To investigate if REST played a role in DIPG 
genesis, SU-DIPG-IV and SU-DIPG-XIII were transduced 
with lentivirus expressing a control shRNA or two different 
shRNA against REST (shRNA1 and shRNA 2). REST 
expression was evaluated by Q-RT-PCR and was found 
to be knocked down by 60% in SU-DIPG-IV and 85% 
in SU-DIPG-XIII cell lines with REST shRNA1 (Figure 
2A). Similarly, 45% and 53% knockdown efficiencies 
were noted with both cell lines, respectively for REST 
shRNA2 (Figure 2A). MTT assays were then performed to 
study the consequence of REST loss on the growth of SU-
DIPG-IV and –XIII cells, in vitro. Growth was measured 
at 24, 48 and 72-hours post-transduction with control or 
REST-specific shRNA. As shown in Figure 2B, REST 
loss decreased cell growth relative to control shRNA 
expressing cells. This ranged between 76%-63% and 50%-
29% for SU-DIPG-IV and -XIII cells, respectively (Figure 
2B). These observations suggest that REST is required to 
sustain DIPG cell growth in vitro.
The requirement for REST in maintaining DIPG 
growth in vivo was examined in a mouse xenograft 
mouse model of DIPG. First, the ability of SU-DIPG-
IV cells to grow in the pons of immunodeficient NOD 
scid gamma (NSG) mice was examined by stereotactic 
implantation of stably expressing firefly luciferase (ffluc) 
cells in mouse pons. Tumor growth was monitored by 
bioluminescence imaging (BLI) once a week. As shown 
in the representative image in Figure 2C (left panel), BLI 
signal was detected 50 days after orthotopic implantation 
of SU-DIPG-IV cells. Kaplan Meier analysis showed that 
all mice (n=6) succumbed to tumors by 20 weeks (Figure 
2C, right panel). The effect of REST loss on tumorigenesis 
was studied through injection of REST-shRNA1 or control 
shRNA-expressing cells into the forebrain [54]. Whereas 
100% of animals (n=8 each) receiving injections of 
control shRNA expressing SU-DIPG-IV cells died within 
7-24 weeks, bioluminescent signal was not observed in 
animals that were implanted with cells expressing REST-
shRNA1 even after 169 days (Figure 2D, left panel, data 
not shown). However, one mouse in the latter group died 
as shown in Figure 2D (right panel). Gross examination 
of the brains revealed a larger tumor burden in mice 
implanted with control shRNA expressing SU-DIPG-
IV cells compared to mice implanted with SU-DIPG-IV 
cells expressing REST-shRNA1 (Supplementary Figure 
1A). Notably, the former group showed both intracranial 
(IC) and extracranial (EC) tumors, whereas substantially 
smaller IC tumors resulted from implantation of cells 
expressing REST-shRNA1 (Figure 2D). Hematoxylin-eosin 
(H&E) staining of the brain sections is shown in Figure 
2E. Immunostaining of brain sections showed significant 
Ki67 positivity in EC and IC in control shRNA expressing 
tumors in contrast to tumors resulting from REST-shRNA1-
transduced cells (Figure 2E-2F and Supplementary Figure 
1B). These observations indicate that REST is required for 
DIPG growth in vivo.
REST modulates vasculature in DIPG tumors 
in vivo, and tube formation in vitro
Interestingly, H&E sections also seemed to 
suggest REST-dependent increases in tumor vasculature. 
To further investigate this, SU-DIPG-IV cells were 
transduced with lentivirus expressing REST shRNA1 or 
control shRNA and equal number of viable cells were 
implanted into the forebrain of NSG mice (n=6). Tumors 
were allowed to grow and mice were sacrificed, their 
brains harvested and sectioned for IHC staining using 
CD31 antibody to mark endothelial cells. As seen in 
Figure 3A, a significant difference in CD31 staining and 
tumor vasculature was observed between REST shRNA1 
and control shRNA expressing intracranial (IC) and 
extracranial (EC) tumors. The number of vessels were 
quantitated to arrive at the plot shown in the right panel 
of Figure 3A (and Supplementary Figure 2A), wherein a 
significant decrease in the number of blood vessels was 
observed in REST shRNA1-expressing tumors compared 
to IC and EC tumors in mice implanted with cells 
expressing control shRNA. Levels of the pro-angiogenic 
receptor VEGFR2 were also found to parallel CD31 
in these tumors (Figure 3B and Supplementary Figure 
Table 1: Immunohistochemical analysis of REST protein expression in FFPE human DIPG specimens
Sample Highest Quantified REST staining Levels
0 + ++ +++ ++++
Normal Brain Stem (2) 1 1
Tumor (19) 2 4 4 5 4
REST expression was scored by a neuropathologist as a negative (0)/ weak and focal (+)/ weak, diffuse or multifocal (++)/ 
strong and focal (+++)/or strong, diffuse or multifocal (++++). Normal brainstem samples are from brainstems that had 
DIPG tumors but were read where tumor was not present.
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Figure 2: REST is required for DIPG growth. (A) Efficiency of REST knockdown following lentiviral transduction of SU-DIPG-
IV and –XIII cells using shRNA against REST or control shRNA was determined by Q-RT-PCR analyses. Significance was found to be 
***p<0.001 (SU-DIPG-IV) and *<0.05 (SU-DIPG-XIII). (B) DIPG growth was assessed using MTT assay. SU-DIPG-IV and SU-DIPG-XIII 
cells transduced with control shRNA or shREST were grown for 24, 48, 72 h, respectively and cell viability was determined by MTT assay 
at the indicated time points. Significance was found to be ***p<0.001 (SU-DIPG-IV), ***<0.001 (SU-DIPG-XIII). (C) Growth of SU-DIPG-
IV- ffluc cells in the pons of NSG mice on day 1 and day 50 after implantation was assessed by bioluminescence imaging after injecting 
SU-DIPG-IV cells into the pons (n=6) (left panel). A Kaplan Meier survival curve is shown in the right panel. (D) Growth of SU-DIPG-
IV-ffluc cells transduced with either control shRNA or REST shRNA into the forebrain of mice (n=8) was monitored by bioluminescence 
imaging (left panel). Kaplan Meier curves were generated to demonstrate a significant (p<0.0001) difference in survival between the 2 
cohorts of mice. (E) H&E staining was performed to show the presence of robust intracranial (IC) and extracranial (EC) tumors in mice 
receiving injections of SU-DIPG-IV-ffluc cells transduced with control shRNA and sparser IC tumors in mice implanted with SU-DIPG-
IV-ffluc cells transduced with REST shRNA. (F) IHC to measure Ki67 staining in tumors described in E. Scale bars in E & F, 50μm (left 
panel); 20μm (right panel).
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2B). These results suggested an involvement of REST-in 
modulation of DIPG vasculature.
In vitro assays were also performed to follow up on 
the above observations. Tube formation assay is a rapid 
and quantitative method to study the effects of compounds 
or conditioned media on formation of blood vessel like 
tubes in matrigel by endothelial cells [55]. To this end, 
human umbilical vein endothelial cells (HUVEC) were 
incubated with the conditioned medium obtained from SU-
DIPG-IV, -VI and -XIII cells transduced with lentiviral 
expressing REST shRNA1 or control shRNA. We observed 
that HUVEC incubated with conditioned medium from 
REST-expressing SU-DIPG-IV, -VI and -XIII cells 
formed significantly higher (2-3 fold) number of tubes in 
matrigel compared to HUVEC incubated with the medium 
from DIPG cells with REST expression knocked down 
(Figure 3C). An increase in HUVEC cell growth was not 
seen under our experimental conditions, indicating that 
the conditioned medium from REST-expressing DIPG 
cells was not due to an effect on HUVEC cell numbers 
(Supplementary Figure 2B). To establish a correlation 
between REST levels and vasculature, human DIPG 
FFPE samples and sections from non-tumor brain stems 
were subjected to IHC using anti-REST and anti-CD31 
antibodies. Two out of three tumor samples were positive 
for REST staining, whereas REST was absent in normal 
brain stem samples. Furthermore, a significant increase 
in the number of blood vessels, as measured by CD31 
staining, was seen in DIPG specimens relative to normal 
controls (Figure 3D, right panel). These observations 
suggest that the increase in CD31 in DIPGs was tumor 
specific and dependent on REST, and was not due to 
normal variations in vasculature in the brain stem.
REST increases GREM-1 secretion
Since VEGFR2 was found to be elevated in DIPG 
xenograft tumors in vivo, we focused on known ligands for 
this receptor. Vascular endothelial growth factor (VEGF) 
is a key ligand for VEGFR2 [56]. We first searched the 
microarray datasets containing gene expression values for 
VEGF expression in human DIPG and normal controls as 
explained in Materials and Methods section. As shown 
in Supplementary Figure 3A-3C, expression of VEGF 
isoforms -A, -B and -C was not significantly different 
between normal controls and DIPG tumors as a group 
or when sub-grouped based on their H3K27M status. 
Analyses of conditioned culture medium from SU-DIPG-
IV, -VI and –XIII cells using a commercially available 
human angiogenesis proteome profiler array kit did not 
reveal VEGF protein in the three cell lines (Supplementary 
Figure 3D). A second ligand that binds VEGFR2, and one 
which is known to promote angiogenesis is Gremlin-1 
(GREM-1) [57–60]. IHC revealed that SU-DIPG-
IV xenografts did indeed express GREM-1 at higher 
levels compare to tumors from REST-deficient isogenic 
cells (Figure 4A). GREM-1 gene expression was also 
detected by Q-RT-PCR in all 3 DIPG lines (Figure 4B), 
supporting GREM-1 as a candidate downstream effector 
of REST-mediated pro-angiogenic effect on HUVEC. 
REST-dependent changes in GREM-1 levels were also 
measured by ELISA, using conditioned medium from 
REST-expressing or REST-deficient SU-DIPG-IV cells. 
A significantly higher level of GREM-1 was detected in 
media from DIPG cells transduced with control shRNA 
compared to medium from shREST DIPG cells (Figure 
4C). Interestingly, a REST-dependent difference in 
GREM-1 gene expression was not observed in DIPG 
patient samples when compared to normal controls, 
with the exception of a small decrease in DIPG MYCN 
subgroup with a very limited number of specimens (Figure 
4D). These findings suggest that REST may control 
GREM-1 at the post-transcriptional level.
GREM-1 promotes tube formation and AKT 
activation in HUVEC and HBMEC
To confirm the effects of GREM-1 on endothelial 
cells, the gene was knocked down in SU-DIPG-IV cells 
lentiviral transduction of two different shRNAs against 
GREM-1 (GREM-1.1 and GREM-1.2). Cells transduced 
with control shRNA were included for comparison. 
Efficiency of GREM-1 knockdown was measured by 
Q-RT-PCR analysis and found to be approximately 85-
90% (Figure 5A). As shown in Figure 5B, GREM-1 loss in 
DIPG cells led to a significant decline in tube formation by 
HUVEC and HBMEC when compared to that supported 
by DIPG cells expressing GREM-1 (Figure 5B and 5C). 
Conversely, addition of recombinant human GREM-1 to 
conditioned medium from shGREM-1.1 expressing DIPG 
cells restored tube formation activity of HUVEC and 
HBMEC (Figure 5B and 5C). As a first step, VEGFR2 
protein expression was detected in HUVEC and HBMEC 
but not in SU-DIPG-IV, -VI and –XIII cells, as measured 
by Western blotting (Figure 5D). A downstream effect of 
GREM-1 interaction with its receptor VEGFR2 is activation 
of AKT signaling [61]. This suggested a paracrine effect of 
GREM-1 on HUVEC and HBMEC (Figure 5E). Together 
these findings suggest that REST elevates GREM-1 
expression, which influences tube formation by endothelial 
cells in a paracrine manner (Figure 6).
DISCUSSION
REST is a regulator of neuronal differentiation genes 
and has been mostly investigated in this context during 
normal brain development and brain tumors [31, 38, 40, 
41, 45, 51, 53]. A recent study also demonstrated a novel 
role for REST in maintenance of genomic integrity during 
S phase in normal neural progenitors [33]. Consistent with 
these observations, REST appears to regulate brain tumor 
cell proliferation and tumor growth [62–65]. Other reports 
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have implicated REST in the control of glioblastoma 
cell migration [66]. Aberrant REST expression has been 
associated with poor outcomes in several neural cancers, 
likely in part due to poor therapeutic response [50, 67]. 
These studies have largely focused on cell intrinsic 
activities influenced by REST. Here, we report both a cell-
intrinsic and a cell-extrinsic contribution of REST towards 
the development of the pediatric brain tumor, DIPG. We 
show for the first time that a significant number of human 
DIPGs had elevated REST gene expression, particularly 
Figure 3: REST expression correlates with increase in number of blood vessels. (A) Mice brains bearing tumors of SU-DIPG-
IV cells expressing control shRNA (top and middle panel) or shREST (bottom panel) were stained with antibodies against the endothelial 
marker, CD31 (left panel). IC=intracranial tumors; EC=extra-cranial tumors. Quantitation of CD31-positive blood vessels between REST-
expressing and REST-deficient DIPG tumors is shown in the right panel. Data shown is mean +/- SD, ***p<0.001, n=4. (B) The above brains 
were also stained with anti-VEGFR2 antibody (left panel) and quantification is provided in the right panel. Data shown is mean +/- SD, 
***p<0.001; n=4. Scale bars in Figure A and B, 50μm (left panel); 20μm (middle panel) and 5 μm in right panel. (C) In vitro tube assay with 
human umbilical vein endothelial cells (HUVEC) were performed by culturing cells in endothelial medium alone or with unconditioned 
DIPG culture medium or endothelial medium with conditioned media from SU-DIPG-IV, -VI and -XIII cells stably transduced with either 
control shRNA or REST-specific shRNA. Endothelial medium and conditioned medium were used in a 1:1 ratio. Tube formation in matrigel 
was photographed after 16h (left panel) and quantitated (right panel). Data shown is mean+/- SD, **p<0.01; ***p<0.001, n=4. Scale bar, 
100μm. (D) Immunohistochemical analysis (IHC) for REST and CD31 in FFPE DIPG tumor specimens (n=3) and normal controls (n=3) 
was performed as described in materials and methods. Scale bar, 100μm. Data shown is for CD31 quantification, mean+/- SD, *p<0.05 
(right panel). CD31 positive blood vessels were counted in four different areas in each normal or tumor sample. An average number of 
vessels from 3 normal control and 3 DIPG tumor samples are shown.
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Figure 4: GREM-1 is secreted by DIPG cells in a REST-dependent manner. (A) Tumor-bearing brains of mice implanted 
with SU-DIPG-IV cells stably expressing either control shRNA or REST-specific shRNA were analyzed by IHC for GREM-1 expression. 
IC=intracranial tumors; EC=extracranial tumors. Scale bars, 200μm (left panel); 50μm (middle panel) and 20 μm in right panel (B) GREM-1 
gene expression in SU-DIPG -IV, -VI and –XIII cells were obtained by Q-RT-PCR measurements. GREM-1 expression was normalized 
to GAPDH. (C) GREM-1 secretion in conditioned medium from SU-DIPG (-IV and -XIII) cells transduced with either control shRNA or 
REST-specific shRNA was measured by ELISA. GREM-1 levels were expressed as pg/mL. Data shown as mean+/- SD, *p<0.05; **p<0.01; 
n=3. (D) Gene expression datasets deposited in GEO were retrieved and analyzed for GREM-1 gene expression using GEO2R as described 
in Materials and Methods. A comparison between normal brain samples (n=10) and DIPG patient samples (n=35) were shown. Each dot 
corresponds to one individual patient. Bars represent mean with standard deviations. *p<0.05; ns=non-significant.
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Figure 5: GREM-1 is required for tube formation in vitro. (A) Q-RT-PCR analysis of GREM-1 gene expression in SU-DIPG-IV 
cells stably expressing either control shRNA or GREM-1-specific shRNA. Lentiviral constructs expressing two different GREM-1 shRNAs 
(GREM-1.1 and GREM-1.2) were used to knockdown GREM-1. Efficiency of GREM-1 knockdown was determined by Q-RT-PCR and 
expression was normalized to 18s RNA. Significance is as shown (**p<0.01) (B-C) HUVEC or human brain microvascular endothelial cells 
(HBMEC) were cultured in endothelial cell medium and or conditioned medium from either control shRNA or shGREM-1.2 transfected 
SU-DIPG-IV cells. Tube formation in matrigel was measured after 16h and images were obtained. The ability of GREM-1 to rescue loss 
of tube formation upon REST knockdown was determined by addition of human-recombinant GREM-1 (rGREM-1) to conditioned media-
endothelial media mix. Scale bars, 100μm. (C) Quantification of tubes in matrigel shown in Figure B (right panels). Data shown is mean +/- 
SD, ***p<0.001, n=3. (D) Western blot analysis to assess VEGFR2 levels in SU-DIPG-IV, -VI and –XIII cells, HUVECs and HBMECs was 
done using anti-VEGFR2 antibodies. Tubulin served as a loading control. (E) Western blot analysis was performed to assess AKT signaling 
downstream of GREM-1 interaction with its potential receptor VEGFR2 in HUVEC and HBMEC. Anti-pAKT (S473), anti-pAKT (T308), 
total AKT, and anti-actin were employed.
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so in the H3K27M-positive samples. Additionally, 20% 
of human DIPGs express REST protein at elevated levels 
compared to normal controls. Although control tissues 
were obtained from “normal” areas distal to the tumor, 
DIPG is a diffusively infiltrative tumor and there certainly 
existed a possibility that stronger REST expression seen 
in our normal controls may be from invasive tumor cells. 
In effect, we may have underestimated the number of 
tumor samples with REST protein elevation. That this 
may indeed be the case is suggested by our observation 
that REST analyses of tumor samples we found that REST 
expression is extremely low to absent in control brain stem 
sections obtained from patients that did not have a brain 
tumor. Consistent with data from other neural tumors such 
as medulloblastoma, neuroblastoma and glioblastoma 
multiforme, REST is also required for maintenance of 
DIPG growth in vitro and in vivo [31, 34, 50]. Although, 
mechanisms remain to be uncovered, REST is known to 
control the expression of molecules involved in regulating 
cell proliferation such as p27 and USP37 [62, 63]. Another 
important area of investigation that needs to be followed 
up in the future centers around the possibility that REST 
activity in concert with histone H3K27 methylation 
may modulate the expression of target genes involved 
in development and lineage specification. Support for 
the above comes from published data which have shown 
an interaction between REST and polycomb repressive 
complex-2 (PRC2) [68, 69]. For example, co-recruitment 
of REST-co-REST-LSD1 and PRC2 to regulatory regions of 
bivalent genes through the long-noncoding RNA, HOTAIR, 
is thought to promote gene repression [68]. Yet other groups 
have shown a mutually exclusive occupancy of REST and 
PRC2 at consensus REST binding sites, known as RE1 
motifs, located near CpG islands of genes [69]. Here, REST 
expression would prevent PRC2 occupancy leading to a 
reduction in histone H3K27 trimethylation and consequent 
gene activation, whereas its loss would promote PRC2 
binding, an increase in histone H3K27 trimethylation and 
silencing of target gene expression. Whether this relates to 
the variable correlation between DNA methylation status 
and histone H3K27 trimethylation at some genes but not 
others in H3K27M mutated DIPG cells, remains to be 
examined [70, 71].
Of additional interest is our finding that REST 
enhances DIPG vasculature. Magnetic resonance imaging 
(MRI) studies in DIPGs have shown that the average 
cerebral blood volumes in areas of occult enhancement 
are significantly higher than non-enhancing areas of the 
same tumor, raising the possibility that tumor development 
is accompanied by an increase in angiogenesis [72]. This 
study is the first to formally validate this observation 
in animal models of DIPG. It is also consistent with a 
previously described role for REST in modulating the 
vasculature in Ewing’s sarcoma [49].
Angiogenesis, a process of sprouting of blood vessels 
from existing ones, is determined by a balance between 
pro-angiogenic factors and angiogenesis inhibitors [73–75]. 
Members of the vascular endothelial growth factor (VEGF) 
and fibroblast growth factor (FGF) family are well-studied 
inducers of angiogenesis [76–80]. Surprisingly, there were 
no significant differences in VEGF mRNA between normal 
controls and DIPG, and VEGF-C protein was not secreted by 
DIPG cells. However, GREM-1, a glycoprotein and member 
of the Dan family of cysteine knot-secreted proteins was 
found to be secreted by the three DIPG cell lines studied [81]. 
GREM-1 is a strong antagonist of signaling through bone 
Figure 6: Model to explain mechanism of REST-mediated control of DIPG vasculature. A pro-angiogenic molecule Gremlin 
is secreted by DIPG in a REST-dependent manner. Gremlin interacts with cell surface receptor VEGFR2 present in endothelial cells and 
causes increased vasculature. In addition, REST also controls DIPG growth.
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morphogenic protein (BMP), a pathway that is believed to 
play an important role in DIPG development [82]. Although a 
number of studies on GREM-1 have examined its function in 
the control of patterning during embryonic development and 
regulation of early limb, lung, kidney and bone development, 
increased GREM-1 expression has also been described in 
various cancers including lung, kidney, ovary, breast, colon 
and pancreatic cancers [83–86]. GREM-1 expression in 
the normal neuronal and astrocytic compartments and its 
interaction with SLIT, a family of axonal guidance proteins, 
has been shown to control chemotaxis of monocytes in 
the brain [87, 88]. In glial-tumors such as GBM, GREM-1 
overexpression in the cancer stem cells (CSCs) compartment 
was found to be necessary to maintain tumor cell growth 
in vitro and in vivo [89, 90]. GREM-1 overexpression in 
glioma cell lines also promoted epithelial to mesenchymal 
transition (EMT) through upregulated expression of 
E-Cadherin and BMP7, and activation of TGF-β signaling 
through engagement of BMP receptors I and II [89]. Of 
specific relevance to observations in our study is the fact 
that GREM-1 is an agonist of vascular endothelial growth 
factor receptor, VEGFR2 [57]. Its interaction with VEGFR2 
is known to control angiogenesis by promoting migration of 
endothelial cells [81]. This is consistent with our findings that 
ectopic GREM-1 expression does not affect endothelial cell 
growth, but does enhance tube formation in vitro. Expression 
of VEGFR2 in HUVEC and HBMEC in vitro and in the 
DIPG tumor vasculature in vivo also supports the possibility 
that GREM-1 acting through VEGFR2 may modulate 
DIPG angiogenesis (Figure 6). However, we cannot rule out 
additional roles for GREM-1 in DIPG development such 
as promoting EMT or immunomodulation, which has been 
described in other tumors [88, 91].
The molecular mechanisms underlying REST-
dependent upregulation of GREM-1 is a subject of 
ongoing investigation. REST is associated with a number 
of chromatin remodeling enzymes, whose activity can be 
inhibited by drugs that are currently in use in the clinic or 
are being investigated in pre-clinical studies [5, 92–94]. 
These agents may have applications in the treatment 
of REST-expressing DIPGs in the future. Finally, our 
results also suggest that the efficacy of VEGF inhibitors 
targeting VEGF alone against these tumors may be 
limited and potential trials considering their use to target 
DIPG vasculature may have need to be re-evaluated [95]. 
Prophylactic anti-Gremlin antibodies have shown promise 
in pulmonary arterial hypertension in mice, which may 
support its examination either alone or in combination 
studies in animal models of DIPG [96].
MATERIALS AND METHODS
Analyses of DIPG samples
Immunohistochemical analyses of normal and tumor 
samples were performed by Dr. Veena Rajaram following 
Institutional Review Board (IRB) approval. Paraffin-
embedded brain sections were immunohistochemically stained 
by hematoxylin eosin (H&E), and REST protein expression 
was analyzed using anti-REST antibody (Cat# IHC-00141; 
Bethyl, Montgomery, TX; 1:100 dilution) followed by DAB 
staining (Vector laboratories, Burlingame, CA). Slides were 
evaluated for REST levels by neuropathologist utilizing a 
5-point grading scale as described in Figure 1A.
Cell culture
SU-DIPG cell lines (IV, VI and XIII) were grown 
under conditions previously described [5]. 293T cells 
were grown in DMEM medium in the absence of serum. 
Human Umbilical Vein Endothelial Cells (HUVEC; 
Cat# CC2519) and EGM-2 bullet kit (endothelial 
basal media and growth factors; Cat# CC3162) were 
purchased from Lonza (Allendale, NJ) and were cultured 
according to manufacturer’s recommendations. Human 
Brain Microvascular Endothelial Cells (HBMEC; Cat# 
HEC02) and Endo-Growth medium were purchased from 
Neuromics (Edina, MN) and cultured in complete Endo-
Growth medium (Cat# MED001) in combination with 
EGM-2 media (1:4 ratio).
Lentivirus production and transduction
293T cells were transfected with lentiviral 
constructs expressing GFP and shRNAs against REST or 
GREM-1 were purchased from M.D. Anderson Cancer 
Center (MDACC) Core facility (shRNA and ORF-eome 
Core) and co-transfected with plasmids pax2 and MD2 
(for packaging) using OptiMEM®I and Lipofectamine® 
2000 Reagent (Cat# 31985-062 and 11668-019, 
Thermo-Fisher Scientific, Waltham, MA) according 
to protocols from MDACC Core facility. Lentiviral 
particles were harvested 48 hours after transfection 
by filtering supernatant using a 70μm syringe filter 
and spinning filtered medium at 1,500 RPM for 5 
minutes. Transduction of SU-DIPG cell lines was done 
by incubating cells with shRNA-expressing lentivirus 
for 72 hours, and then flow sorted for GFP positive 
DIPG cells at the MDACC Cell Sorting Core facility. 
Knockdown of REST or GREM-1 was confirmed by 
Q-RT-PCR. For in vivo experiments, GFP positive 
REST-knockdown SU-DIPG-IV cells were transduced 
with firefly luciferase co-expressing Mkate lentivirus 
and sorted for mKate. These cells were injected into 
NSG mice to develop tumors. Nucleotide sequences 
for shRNAs purchased from the shRNA and ORF-eome 









RNA was isolated from cells using Zymo Research 
Quick-RNATM MiniPrep Kit (Cat# 11-328; Genesee 
Scientific, San Diego, CA 11-328) and resuspended in 
water. RNA was quantified using NanoDrop 1000 
(Thermos Fisher Scientific, Wilmington, DE). At least 
300ng of RNA from each sample was reverse-transcribed 
using the Bio-Rad iScriptTM cDNA Synthesis Kit (Cat# 
170-8891; Bio-Rad, Hercules, CA). Reverse transcription 
was completed on the Bio-Rad T100 Thermal Cycler (Bio-
Rad, Hercules, CA). qPCR was performed on the Roche 
LightCycler® 96 using Roche LightCycler® 480 SYBR 
Green I Master mix (Cat# 04707516001; Roche, 
Indianapolis, IN) and 0.5μL of 10mM each primer. 
Relative mRNA expression after normalizing to GAPDH 
or 18s was determined by the comparative 2-ΔΔCT 
method [97]. Primer sequences are as below.
MTT assay
SU-DIPG-IV and /or SU-DIPG-XIII cells were 
plated in a 96-well plate at a density of 6,000 cells/well 
in 100μL complete media. At various times (24, 48 or 
72h) after lentiviral transduction with control shRNA or 
REST-shRNA, 50μL of media was decanted, and 25ng of 
98% Thiazolyl Blue Tetrazolium Bromide (MTT) (Cat# 
M2128-1G; Sigma, St. Louis, MO) was added. Cells 
were incubated for 2-4 hours before 100 μl of DMSO was 
added to each well and triturated to uniformly suspend 
the MTT precipitate. Plates were read for absorbance 
(570/650 nm) with a SPECTRAmax®PLUS384 Microplate 
Spectrophotometer (Molecular Devices, Sunnyvale, CA).
In vivo assays
All animal experiments and procedures were 
approved by the Institutional Animal Care and Use 
Committee (IACUC). SU-DIPG cells were injected into 
the pons or forebrain of 4-6 month old NOD scid gamma 
null (NSG; NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX) mice 
(The Jackson Laboratory, Bar Harbor, ME) [54]. SU-
DIPG-IV stably expressing firefly luciferase (ffluc) were 
suspended in sterile PBS prior to employing a sterile 
field for injection of either 1 million SU-DIPG-IV-ffluc 
into the pons (1mm posterior to lamboid suture, 1mm 
lateral to midline, 5mm below skull surface) or 500,000 
SU-DIPG-IV-ffluc into the forebrain (1.5mm anterior 
to lamboid, 2.5mm right of midline, 2mm deep), using 
a Harvard Apparatus (Holliston, MA) and 26 guage gas 
tight Hamilton syringe. Mice were anesthetized using 
2-4% inhalant isoflurane prior to the surgical procedure. 
Bioluminescent imaging of DIPG tumors was performed 
using the Caliper LifeSciences IVIS Spectrum IVIS200 
in vivo imaging system (Hopkinton, MA). Mice were 
injected with 150mg/kg with D-Luciferin (Cat# E1605; 
Promega Corporation, Madison, WI) through an 
intraperitoneal (IP) route, and sacrificed upon onset 
of clinical signs or signs of solid tumors formed in the 
brain and grown through skull. Brains were collected and 
sectioned for IHC analysis.
Immunohistochemistry
Mice brain tissues were fixed in 10% neutral buffered 
formalin and embedded in paraffin blocks. 4-μm-thick 
brain sections were cut and used for immunohistochemical 
(IHC) analysis. After deparafinization and rehydration, 
heat-mediated antigen retrieval and blocking, sections 
were incubated with primary antibodies to REST (Cat# 
IHC-00141; Bethyl, Montgomery, TX), CD31 (Cat# 
ab28364; Abcam, Cambridge, MA), VEGFR2 (Cat# 
2479; Cell Signaling Technology, Danvers, MA), Ki67 
(Cat# AB9260; Millipore, Billerica, MA), and Gremlin-1 
(Cat# PA5-13123; Thermo-Fisher Scientific, Waltham, 
MA) at 4°C overnight. After washing, sections were 
incubated with secondary antibody conjugated to horse 
radish peroxidase (Cat# 111-035-003 and Cat# 115-035-
003; Jackson ImmunoResearch Labs, West Grove, PA) for 
2 h at room temperature. All incubations were performed 
under humidified conditions. After washing, slides 
were developed using 3,3′-diaminobenzidine substrate 
(DAB; Cat# Vector Laboratories, Burlingame, CA), 
counterstained with hematoxylin, dehydrated, mounted 
and visualized under a microscope (Nikon ECLIPSE 
E200; Melville, NY). Images were obtained using an 
Olympus SC100 camera (Waltham, MA) attached to the 
microscope. Images were processed using CellSens Entry 
microscopy imaging software (Olympus Life Sciences, 
Waltham, MA).
In vitro angiogenesis assay
In vitro angiogenesis assay (tube formation assay) 
was performed as described previously [98]. Briefly, 
Matrigel (Cat# 354230; Thermo Fisher Scientific, 
Waltham, MA; 100 μl/well) was placed in 96 well sterile 
culture plates. HUVEC or HBMEC (5 × 104 cells per 
25μL) mixed in conditioned medium from DIPG or 










plain DIPG medium (1:1 ratio) were placed on top of 
the matrigel and incubated in a CO2 incubator at 37°C. 
After 16 h, cells were stained with Calcein-AM (Cat# 
C3100MP; Thermo Fisher Scientific, Waltham, MA) for 
30 min, rinsed with the endothelial cell medium. Tube 
formation in matrigel was visualized under a fluorescence 
microscope (Nikon Eclipse Ti-E, Melville, NY) and 
images were taken with a camera (Andor, Zyla, Concord, 
MA) attached to the microscope. Image analysis and 
quantification was done using NIS elements AR software 
(Nikon, Melville, NY).
Western blot analysis
Cell lysates were prepared by lysing DIPG cells or 
HUVEC or HBMEC in EBC lysis buffer (50 mM Tris, 
pH 8.0, 120 mM NaCl, and 0.5% NP-40) supplemented 
with protease inhibitors (Thermo Fisher Scientific, 
Waltham, MA) and phosphatase inhibitor cocktail-2 
(Sigma, St. Louis, MO). Lysates were clarified and protein 
concentration in supernatants was measured using Bio-
Rad protein assay dye reagent (Bio-Rad Laboratories, 
Hercules, CA). Samples were then subjected to SDS-
PAGE and Western blot analyses with the following 
primary antibodies: REST (Cat# 07579; Millipore, 
Billerica, MA), pAKTSer473 (Cat# 9271, Cell Signaling 
Technology (CST), Danvers, MA) p-AKTT308, (Cat# 5106; 
CST, Danvers, MA), AKT (Cat# 9272; CST, Danvers, 
MA), VEGFR2 (Cat# 2479; CST, Danvers, MA) and 
Tubulin-HRP (Cat# ab40742; Abcam, Cambridge, MA). 
After washing and incubation with the corresponding 
HRP-conjugated secondary antibodies (Jackson Immuno 
Research, West Grove, PA), membranes were developed 
using SuperSignal (Cat# 34075; Cat#34087; Thermo-
Scientific, Waltham, MA) followed by autoradiography.
Human angiogenesis proteome profiler assay
Proteome profiler human angiogenesis array kit 
(Cat# ARY007, R&D Systems Minneapolis, MN) was 
used to measure expression of 55 angiogenesis related 
proteins including VEGF-C. Conditioned media from 
SU-DIPG (-IV, -VI and -XIII) cells were collected for the 
assay as per manufacture’s conditions.
ELISA
GREM-1 levels in DIPG conditioned medium were 
quantified using a ELISA kit according to manufacturer’s 
recommendations (Neo BioLab, Woburn, MA).
GEO2R analysis
Microarray datasets containing the gene expression 
values of diffuse intrinsic pontine glioma (DIPG) patients 
were obtained from Gene Expression Omnibus (www.
ncbi.nlm.nih.gov/geo). We used GSE50025 dataset which 
contained Illumina HT-12 V4 BeadChip Array profiling 
of 35 DIPG samples and 10 normal brain controls [16] to 
evaluate gene expression. The data were analyzed through 
the GEO2R interface (http://www.ncbi.nlm.nih.gov/geo/
geo2r/) as previously described [99]. Microarray data were 
normalized in Partek Genomics Suite v6.6 using per-probe 
median-centered quantile normalization. p-values for 
comparisons between sample groups were obtained using 
the unpaired t-test with Welch’s correction.
Statistical analysis
Experimental data reported was Mean ± SD 
of a minimum of 3 samples. A P value of < 0.05 was 
considered to be statistically significant. Student’s t test 
was performed for significance between groups. GraphPad 
Prism version 6.01 for Windows (GraphPad Software, San 
Diego, CA) was used to generate graphs.
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